NYSE:AZNAstraZeneca Stock Price, Forecast & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZN stock has increased by 17.7% and is now trading at $52.47. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) released its quarterly earnings data on Wednesday, April, 29th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.06. The firm earned $6.35 billion during the quarter, compared to the consensus estimate of $5.95 billion. AstraZeneca had a net margin of 5.94% and a return on equity of 33.97%. AstraZeneca's revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter last year, the business posted $0.89 earnings per share. View AstraZeneca's earnings history.

AstraZeneca announced a semi-annual dividend on Tuesday, February 18th. Investors of record on Friday, February 28th will be paid a dividend of $0.95 per share on Monday, March 30th. This represents a yield of 2.8%. The ex-dividend date is Thursday, February 27th. View AstraZeneca's dividend history.

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

8 brokers have issued 12-month target prices for AstraZeneca's stock. Their forecasts range from $55.00 to $60.00. On average, they anticipate AstraZeneca's stock price to reach $57.50 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price. View analysts' price targets for AstraZeneca.

Media headlines about AZN stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AbbVie (ABBV), AT&T (T), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Bank of America (BAC) and Johnson & Johnson (JNJ).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (2.57%), Primecap Management Co. CA (2.16%), Jennison Associates LLC (1.48%), Capital International Investors (1.08%), Fisher Asset Management LLC (0.63%) and Invesco Ltd. (0.41%). View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Russell Investments Group Ltd., Eaton Vance Management, Magnetar Financial LLC, Cookson Peirce & Co. Inc., Voloridge Investment Management LLC, Waddell & Reed Financial Inc., and Parametric Portfolio Associates LLC. View insider buying and selling activity for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, BlackRock Inc., Wellington Management Group LLP, Jennison Associates LLC, Invesco Ltd., Capital World Investors, Sphera Funds Management LTD., and Nuveen Asset Management LLC. View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $52.47.

AstraZeneca has a market capitalization of $137.70 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]